

S3 Table. Clinicopathologic characteristics of patients with high-grade serous carcinoma

Characteristic	Total (n=368)	<i>BRCA</i> wild-type (n=246)	<i>BRCA</i> mutation (n=122)	p-value
Age (yr)	55.9±10.0	56.9±10.2	54.0±9.4	0.010
Parity	2.1±1.2	2.1±1.3	2.0±1.1	0.410
Origin				0.637
Ovary	342 (92.9)	227 (92.3)	115 (94.3)	
Fallopian tube	12 (3.3)	8 (3.3)	4 (3.3)	
Peritoneum	14 (3.8)	11 (4.5)	3 (2.5)	
Hx of BC	45 (12.2)	21 (8.5)	24 (19.7)	0.002
Hx of other cancers	13 (3.5)	8 (3.3)	5 (4.1)	0.766
Family Hx of POFTC	21 (5.7)	5 (2.0)	16 (13.1)	< 0.001
Family Hx of BC	35 (9.5)	12 (4.9)	23 (18.9)	< 0.001
Family Hx of other cancers	77 (20.9)	48 (19.5)	29 (23.8)	0.344
FIGO stage				0.308
I	16 (4.3)	12 (4.9)	4 (3.3)	
II	30 (8.2)	24 (9.8)	6 (4.9)	
III	217 (59.0)	144 (58.5)	73 (59.8)	
IV	105 (28.5)	66 (26.8)	39 (32.0)	
CA-125 (IU/mL)	929.0 (3.4-17313)	972.0 (3.4-15700)	794.5 (5.1-17313)	0.474
Primary treatment strategy				0.897
PDS	255 (69.3)	171 (69.5)	84 (68.9)	
NAC	113 (30.7)	75 (30.5)	38 (31.1)	
Residual tumor after PDS/IDS ^{a)}				0.533
No gross	253 (68.8)	173 (70.3)	80 (65.6)	
< 1 cm	58 (15.8)	38 (15.4)	20 (16.4)	
1-2 cm	22 (6.0)	12 (4.9)	10 (8.2)	
≥ 2 cm	19 (5.2)	14 (5.7)	5 (4.1)	
Unknown	11 (3.0)	5 (2.0)	6 (4.9)	
Recurrence ^{b)}	247 (67.1)	164 (66.7)	83 (68.0)	0.793
PSR ^{c)}	195 (53.0)	122 (49.6)	73 (59.8)	0.017
PRR	51 (13.9)	41 (16.7)	10 (8.2)	
Genetic test methods				0.370
Germline only	294 (79.9)	192 (78.0)	102 (83.6)	
Somatic only	23 (6.3)	18 (7.3)	5 (4.1)	
Both	51 (13.9)	36 (14.6)	15 (12.3)	
<i>BRCA1</i> mutational status				<0.001
Wild-type	280 (76.1)	246 (100.0)	34 (27.9)	
Mutation	88 (23.9)	0	88 (72.1)	
<i>BRCA2</i> mutational status				<0.001
Wild-type	333 (90.5)	246 (100.0)	87 (71.3)	
Mutation	35 (9.5)	0	35 (28.7)	

Values are presented as mean±SD, number (%), or median (range). Hx, history; BC, breast cancer; POFTC, peritoneal, ovarian, and fallopian tubal cancers; FIGO, International Federation of Gynecology and Obstetrics; CA-125, cancer antigen 125; PDS, primary debulking surgery; NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery; PSR, platinum-sensitive recurrence; PRR, platinum-resistant recurrence; SD, standard deviation.

^{a)}Five patients did not receive debulking surgery, ^{b)}Among the recurred, one patient did not receive taxane- and platinum-based chemotherapy before, ^{c)}PSR was defined as relapse ≥ 6 months after completion of taxane- and platinum-based chemotherapy, whereas PRR as relapse < 6 months.